Autolus Therapeutics (AUTL) Q4 2019 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2019 earnings summary
9 Nov, 2026Executive summary
Pre-revenue developer of programmed T-cell cancer therapies; no approved products or product-sales revenue in the 15-month period ended 31 December 2019.
Reporting period covers 15 months after the financial year-end changed from 30 September to 31 December; prior IFRS comparison covers 12 months.
Financial highlights
IFRS operating loss was £132.9m and net loss £113.5m for the 15-month period; prior 12-month losses were £40.4m and £31.1m, respectively.
R&D expense was £91.0m and administrative expense £41.3m; R&D included higher clinical study costs and share-based compensation.
Other operating income was £2.6m, finance income £7.0m and finance expense £1.7m; income tax credit was £14.1m.
Cash and cash equivalents were £159.3m at 31 December 2019, compared with £189.3m at 30 September 2018.
Outlook and guidance
Available cash, including the January 2020 financing, was expected to fund planned operating expenses and capital needs for at least 12 months; directors forecast cash extending into early 2022.
Significant expenses and operating losses expected to continue as candidates advance through clinical development, regulatory review and potential commercialization.
Planned milestones included AUTO1 adult ALL Phase 2 initiation in 2020, AUTO4 interim data in Q4 2020 and AUTO8 Phase 1 initiation in 2020.
Latest events from Autolus Therapeutics
- AUCATZYL scales commercially as margin gains and new indications build the next growth drivers.AUTL
Jefferies Global Healthcare Conference - AUCATZYL growth and expanding obe-cel trials broaden the commercial opportunity.AUTL
Corporate presentation - AUCATZYL revenue rose 95%, gross margin reached 57%, and FY2026 guidance is at least $150M.AUTL
Q3 2026 - IPO-funded cash supports expanding T-cell trials, but losses and clinical risks remain significant.AUTL
Q4 2018 - Cash runway extended to May 2023 as clinical development drives continued losses.AUTL
Q4 2021 - Licensing growth and a £316.3m cash balance offset a wider loss, with funding needed beyond June 2024.AUTL
Q4 2022 - Obe-cel advanced toward a 2024 decision, backed by encouraging data and $600M in February proceeds.AUTL
Q4 2023 - Resale registration for 3.5M ADSs linked to a warrant, supporting T cell therapy expansion.AUTL
Registration filing - Q2 2026 revenue surged 119% year-over-year, with gross margin at 55% and guidance raised.AUTL
Q2 2026